Effect of intramuscular versus sublingual atropine to decrease salivary secretion in oral surgeries
Not Applicable
- Conditions
- Health Condition 1: Q670- Congenital facial asymmetry
- Registration Number
- CTRI/2020/11/029242
- Lead Sponsor
- Dr Sneha
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Individuals aged 10-30 years, undergoing elective surgeries, under general anesthesia, Requiring antisialagogue premedication, American Society of Anesthesiologists (ASA) Physical Status 1 and 2
Exclusion Criteria
Presence of significant oral pathology like oral malignancies, recent history of aphthous ulcers,Patients with history of urinary retention, Patients with severe cardiorespiratory disorders,Patients with xerostomia and/or xeropthalmia, Any allergy to atropine, History of smoking, History of recent or current upper respiratory tract infection,Angle closure glaucoma, Severe hepatic and renal diseases, Patient on any medications interfering with salivation
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To compare the quantity of saliva produced 45 minutes after introducing atropine via sublingual and intramuscular routes in gramsTimepoint: 45 minutes
- Secondary Outcome Measures
Name Time Method 1.To assess and compare dryness caused by atropine administered via sublingual and intramuscular routes <br/ ><br>2.To estimate the changes in cardiovascular system by atropine via sublingual and IM routes by non-invasive blood pressure (systolic BP, diastolic BP, mean arterial pressure), heart rate, temperature <br/ ><br>Timepoint: HR - beats/minute <br/ ><br>BP- mm Hg <br/ ><br>temperature- degree celcius